List of Excipients in Branded Drug MEGACE ES

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Atlantic Biologicals Corps	MEGACE ES	megesterol acetate	17856-0949	CITRIC ACID MONOHYDRATE
Atlantic Biologicals Corps	MEGACE ES	megesterol acetate	17856-0949	DOCUSATE SODIUM
Atlantic Biologicals Corps	MEGACE ES	megesterol acetate	17856-0949	HYPROMELLOSE 2208
Atlantic Biologicals Corps	MEGACE ES	megesterol acetate	17856-0949	LEMON
Atlantic Biologicals Corps	MEGACE ES	megesterol acetate	17856-0949	LIME

Megace ES Excipient Strategy and Commercial Opportunities

Last updated: August 9, 2026

Megace ES is a high-strength oral suspension of megestrol acetate used to treat anorexia, cachexia, or significant weight loss in patients with AIDS. Its commercial value is linked to dose concentration, palatability, physical stability, and the ability to deliver 625 mg in 5 mL. The formulation uses sucrose, polysorbate 80, xanthan gum, citrate buffering agents, and flavoring. The main commercial opportunities are generic substitution, lower-sugar reformulation, improved taste, ready-to-use packaging, and alternative megestrol acetate suspension platforms.

What is Megace ES and how does its formulation work?

Megace ES contains 625 mg of megestrol acetate per 5 mL of oral suspension, equivalent to 125 mg/mL. The product is substantially more concentrated than the earlier Megace oral suspension, which contained 800 mg per 20 mL, or 40 mg/mL.[1]

Product	Active ingredient	Strength	Dosage form	Primary formulation advantage
Megace ES	Megestrol acetate	625 mg/5 mL	Oral suspension	High concentration and smaller administration volume
Earlier Megace suspension	Megestrol acetate	800 mg/20 mL	Oral suspension	Lower concentration, larger dose volume
Megestrol acetate tablets	Megestrol acetate	Commonly 20 mg or 40 mg	Tablet	No suspension handling, but higher tablet burden at therapeutic doses

The higher concentration reduces the volume required for the labeled adult dose of 800 mg daily. A patient taking 800 mg per day requires approximately 6.4 mL of Megace ES, compared with 20 mL of the 40 mg/mL suspension.

The formulation is a dispersed oral suspension rather than a true solution. Excipients must maintain uniform drug distribution, limit sedimentation and caking, preserve redispersibility, control taste, and support accurate dosing.

What excipients are used in Megace ES?

The FDA labeling identifies sucrose, citric acid monohydrate, polysorbate 80, sodium citrate dihydrate, xanthan gum, flavoring, and purified water or equivalent aqueous vehicle components as inactive ingredients.[1]

Excipient	Formulation role	Commercial and technical relevance
Sucrose	Sweetener, mouthfeel modifier, solids contributor	Improves palatability but creates sugar-load and dental-risk concerns
Citric acid monohydrate	Acidulant and pH adjustment	Supports taste and pH control
Sodium citrate dihydrate	Buffering agent	Stabilizes pH and moderates acidity
Polysorbate 80	Wetting and dispersing aid	Helps distribute hydrophobic megestrol acetate particles
Xanthan gum	Suspending and viscosity agent	Supports dose uniformity and reduces rapid settling
Flavoring	Taste masking	Important because megestrol acetate suspensions must be acceptable at relatively high drug concentrations
Water	Continuous phase	Determines viscosity, microbial-control requirements, and physical stability

Megestrol acetate is poorly water soluble. The excipient system therefore must manage particle wetting and suspension behavior rather than dissolve the full drug load. Polysorbate 80 can improve wetting of hydrophobic particles, while xanthan gum increases viscosity and slows sedimentation.

The formulation tradeoff is important. Excessive viscosity can make the product difficult to pour, withdraw through an oral syringe, or rinse from the container. Insufficient viscosity can cause rapid settling and dose nonuniformity. A commercial reformulation must optimize both physical stability and administration performance.

What excipient attributes are critical for Megace ES?

Suspending-agent performance

Xanthan gum is a practical choice because it provides viscosity at low use levels and has broad regulatory acceptance in oral products. Its performance depends on grade, hydration, mixing order, shear history, ionic strength, and pH.

A generic manufacturer should characterize:

• Sedimentation rate
• Redispersibility after storage
• Particle-size distribution
• Viscosity at multiple shear rates
• Dose uniformity from the beginning, middle, and end of the container
• Withdrawal accuracy through the proposed dosing device
• Behavior after storage at refrigerated and elevated temperatures

A suspension can meet appearance specifications and still fail dose uniformity if the sediment compacts or the drug is poorly wetted.

Surfactant selection

Polysorbate 80 is used to improve wetting and dispersion of megestrol acetate. Its concentration requires control because excessive surfactant can affect taste, foaming, viscosity, and physical stability.

Potential alternatives include polysorbate 20, poloxamers, lecithin-based systems, or specialized wetting agents. Each substitution can alter dissolution, particle aggregation, preservative performance, and bioequivalence. A change in surfactant is not a cosmetic adjustment. It can affect the drug product's critical quality attributes.

Sugar and taste strategy

Sucrose supports a familiar sweet taste and can improve mouthfeel. Its disadvantages include:

• High carbohydrate exposure at repeated doses
• Dental-health concerns
• Poor suitability for some patients with diabetes or metabolic complications
• Increased osmotic load
• Potentially higher microbial-growth risk if preservation is inadequate

A low-sugar or sugar-free product could have commercial value, especially if it maintains palatability without increasing bitterness or aftertaste. Candidate systems could use sorbitol, glycerin, sucralose, acesulfame potassium, or combinations of polyols and high-intensity sweeteners.

A sugar-free product would require new comparative testing for viscosity, water activity, microbial limits, preservative effectiveness, and gastrointestinal tolerability. Polyols can cause gastrointestinal effects at meaningful doses. High-intensity sweeteners can produce a delayed or metallic aftertaste that may be more problematic than the original formulation.

Buffer system

The citric acid and sodium citrate combination provides pH control and contributes to taste. A reformulation should preserve a pH range that supports:

• Physical stability
• Chemical stability
• Acceptable taste
• Preservative performance, if preservatives are used
• Compatibility with the bottle, cap, liner, and dosing device

A shift toward phosphate or alternative citrate buffering may be possible, but it could change ionic strength and xanthan-gum performance. The buffer system must therefore be evaluated as part of the complete suspension rather than as an isolated excipient change.

What formulations are protected by Megace ES?

Megace ES is primarily differentiated by its high-strength oral suspension formulation and dose-volume reduction. The commercial protection historically associated with the product was more likely to arise from the branded product, FDA approval, formulation know-how, and regulatory exclusivity than from a broad, durable patent barrier around common excipients.

The Orange Book should be reviewed for current patent listings and regulatory exclusivity associated with the relevant NDA.[2] Patent status can change through listing updates, delistings, expiration, litigation, or approved product changes. A patent search should cover:

• Megestrol acetate oral suspension claims
• High-concentration suspension claims
• Particle-size and wetting claims
• Taste-masking claims
• Redispersibility and dose-uniformity claims
• Packaging and oral-dosing-device claims
• Method-of-use claims for AIDS-related anorexia and cachexia

Common excipients such as sucrose, citrate, xanthan gum, and polysorbate 80 generally provide limited standalone patent differentiation. Stronger protection would require a defined combination or performance limitation, such as a specific particle-size distribution, viscosity profile, sedimentation rate, concentration range, or dosing-volume advantage.

When does Megace ES lose exclusivity?

Megace ES has no biologic biosimilar pathway because megestrol acetate is a small-molecule active pharmaceutical ingredient. Competitive entry would occur through an ANDA, a 505(b)(2) application, or, in some cases, a new drug application.

The relevant exclusivity categories are:

Exclusivity type	Relevance to Megace ES
New chemical entity exclusivity	Unlikely to remain relevant for an older megestrol acetate product
Three-year exclusivity	Could apply to certain qualifying changes, but must be confirmed in FDA records
Orphan-drug exclusivity	Not generally associated with the AIDS cachexia indication
Pediatric exclusivity	Would require a specific FDA grant
Patent protection	Must be assessed through the current Orange Book and patent records
Regulatory exclusivity for a new formulation	Possible for qualifying reformulations, subject to FDA requirements

For an established product, the practical entry question is whether a current patent or unexpired regulatory exclusivity blocks approval or commercial launch. The absence of a meaningful barrier can support generic competition even if the reference product remains commercially marketed.

What FDA pathway applies to a generic Megace ES?

A conventional generic would generally seek approval under section 505(j) of the Federal Food, Drug, and Cosmetic Act through an ANDA. The applicant would need to demonstrate pharmaceutical equivalence and bioequivalence to the reference listed drug, along with appropriate manufacturing and quality controls.[3]

For an oral suspension, the development package must address more than active-ingredient strength. Relevant issues include:

• Same active ingredient and concentration
• Equivalent dosage form
• Comparable inactive-ingredient functionality
• Drug-content uniformity
• Particle-size distribution
• In vitro dissolution or release behavior, as applicable
• Comparative pharmacokinetics
• Container-closure compatibility
• Microbiological quality
• Shake instructions and dose-delivery performance

A 505(b)(2) pathway could be commercially useful for a materially different formulation, such as a sugar-free product, a longer-stability product, or a formulation with a distinct dosing device. The applicant would need to establish the bridge to existing safety and efficacy data while supporting the differences that are not covered by the reference product.

Are there Paragraph IV challenges to Megace ES?

Paragraph IV risk depends on the current Orange Book patent listings for the reference NDA and any later-listed patents. A generic applicant that determines an applicable patent is invalid, unenforceable, or not infringed may submit a Paragraph IV certification. The reference sponsor can then file patent litigation, potentially triggering a 30-month stay of approval under the Hatch-Waxman framework.[4]

For Megace ES, the relevant diligence questions are:

1. Which patents, if any, are currently listed against the reference NDA?
2. Are the listed patents formulation, method-of-use, or manufacturing patents?
3. Have any generic applicants submitted Paragraph IV certifications?
4. Has litigation been filed in federal district court?
5. Have settlement agreements restricted launch timing?
6. Does the FDA approval status show tentative or final approval for competing products?

No biosimilar litigation analysis is required because megestrol acetate is not a biologic. Generic litigation and ANDA certification risk are the relevant competitive issues.

How strong is the Megace ES patent estate?

The estate should be viewed as moderate to weak unless current records identify live, enforceable patents covering the high-strength suspension or a commercially necessary formulation feature.

Patent-estate factor	Assessment
Active ingredient	Mature small molecule with limited composition-of-matter value
Conventional excipients	Weak protection when claimed individually
High-strength suspension	Potentially meaningful if claims are narrow and technically supported
Dose-volume reduction	Commercially valuable, but difficult to protect broadly
Method of use	Potentially relevant, but indication scope and enforceability matter
Manufacturing process	Can delay copying if process-specific and difficult to design around
Regulatory exclusivity	Likely more important for new formulation launches than legacy product sales
Generic substitution risk	Material if no live blocking patents remain

The strongest defensible claims would likely combine active concentration with measurable formulation parameters. A claim directed only to a list of conventional excipients would face substantial validity and design-around risks.

What commercial opportunities exist for Megace ES excipients?

Sugar-free or reduced-sugar Megace suspension

The most visible opportunity is a sugar-free or reduced-sugar suspension. The product could target patients who need calorie support but have diabetes, dental concerns, or intolerance to high-sugar medicines.

Commercial success would depend on taste. A sugar-free formulation that produces poor adherence would have limited value even if it offers a cleaner excipient profile.

Improved oral dosing

An oral syringe, calibrated cup, or unit-dose container could reduce dosing errors. A 125 mg/mL suspension creates a relatively small administration volume, making device accuracy important.

A commercially differentiated product could provide:

• A bottle adapter for oral-syringe withdrawal
• A tamper-evident, ready-to-use package
• Unit-dose cups for institutional settings
• Clear shake instructions
• A dosing device calibrated in both milliliters and milligrams

Packaging and device claims may provide supplementary IP protection, although they are unlikely to create a durable barrier alone.

Ready-to-use and stability-enhanced products

A formulation with improved room-temperature stability, reduced settling, or longer in-use stability could reduce pharmacy and caregiver burden. Opportunities include:

• Better sedimentation control
• Reduced caking
• Lower foaming during shaking
• Improved preservative robustness
• More compact packaging
• Longer open-bottle use period

These improvements would require stability studies under ICH conditions and in-use testing after repeated opening and dosing.

Taste-masked and patient-centered products

Megace ES is administered to patients who may already have poor appetite, weakness, nausea, or swallowing difficulty. Taste and mouthfeel therefore have direct commercial relevance.

Potential approaches include:

• More effective flavor masking
• Lower acidity
• Reduced viscosity after pouring
• Smooth rather than chalky mouthfeel
• A smaller dose volume without increasing unpleasant taste intensity

Flavor systems are difficult to protect broadly, but proprietary combinations and performance-based formulation claims can support differentiation.

Institutional and global-market formats

Hospitals, skilled-nursing facilities, hospices, and specialty pharmacies may value unit-dose packaging and simplified administration. International markets may also favor lower-cost excipient systems or packaging that tolerates temperature variation.

Geographic opportunities depend on local registration status, reference-product requirements, excipient permissions, and reimbursement. The U.S. market remains governed by FDA reference-product and ANDA requirements, while other jurisdictions may apply different bioequivalence and formulation-bridging standards.

How does Megace ES compare with tablets and other appetite-stimulant products?

Megace ES has a clear administration advantage over tablets when the required daily megestrol acetate dose is high. Tablets can impose a substantial pill burden, while the suspension allows dose administration in several milliliters.

Attribute	Megace ES	Megestrol tablets	Other appetite-stimulant products
Dose flexibility	High	Moderate	Varies
Swallowing burden	Low	Higher	Varies
Excipient sensitivity	High	Lower	Product-specific
Dose-volume advantage	Strong	Not applicable	Varies
Taste risk	High	Low	Product-specific
Generic substitution	Suspension-specific	Tablet-specific	Depends on product
Sugar-free differentiation	Directly relevant	Usually less relevant	Product-specific

Megace ES competes on administration, not only on active ingredient. A generic with the same strength but weaker suspension behavior or poorer taste may lose meaningful market share to the reference product.

What generic launch risks exist for Megace ES?

The principal launch risks are formulation and regulatory, not biologic comparability. A candidate product can fail commercially through:

• Inadequate redispersibility
• Dose nonuniformity during container use
• Poor taste
• Clogging or inaccurate oral-syringe delivery
• Excessive viscosity
• Microbial-control failures
• Incompatible packaging
• Weak evidence supporting a formulation change
• Patent or regulatory exclusivity blocking final approval
• Low market value after price erosion

Revenue exposure for the branded product is highest if a generic matches the 625 mg/5 mL concentration, uses a familiar dosing device, receives substitutable approval, and launches without a settlement restriction. A lower-strength generic may not compete directly because it increases administration volume.

Key Takeaways

• Megace ES is a 125 mg/mL megestrol acetate oral suspension.
• Its excipient system relies on sucrose for sweetness, polysorbate 80 for wetting, xanthan gum for suspension control, and citrate salts for pH management.
• The principal formulation opportunity is a sugar-free or reduced-sugar product with equivalent taste and physical stability.
• Generic development requires control of sedimentation, redispersibility, dose uniformity, viscosity, particle size, and dosing-device performance.
• Megace ES has no biosimilar risk because megestrol acetate is a small molecule.
• Paragraph IV exposure depends on current Orange Book-listed patents and any related litigation or settlement agreements.
• Strong patent protection would require specific formulation, process, or performance claims rather than broad claims to common excipients.
• Commercial differentiation can come from taste masking, ready-to-use packaging, oral-syringe accuracy, improved stability, and institutional unit-dose formats.

FAQs

Can xanthan gum be replaced in a Megace ES generic?

Yes. A substitute such as sodium carboxymethylcellulose, microcrystalline cellulose with carboxymethylcellulose, or a polymer blend may be technically feasible. The replacement would require comparative testing for viscosity, sedimentation, redispersibility, dose uniformity, taste, and bioequivalence.

Is a sugar-free Megace ES formulation commercially attractive?

Yes, particularly for patients with diabetes, dental concerns, or sensitivity to high-sugar medicines. The opportunity depends on achieving acceptable taste and avoiding gastrointestinal effects from polyols or aftertaste from high-intensity sweeteners.

Does Megace ES require a preservative?

The requirement depends on the final formulation, packaging, water activity, microbial-control strategy, and in-use period. A preservative-free product may be possible with suitable packaging and validated microbiological controls, but it cannot be assumed from the reference formulation alone.

Can a generic use different flavors from Megace ES?

A generic can use different inactive ingredients when permitted by FDA requirements and supported by the application. The alternative flavor must not compromise safety, quality, bioequivalence, stability, or patient acceptability.

What is the most defensible IP strategy for a new megestrol acetate suspension?

The strongest strategy would combine formulation and process claims covering concentration, particle-size distribution, wetting behavior, viscosity, redispersibility, dosing accuracy, stability, or a distinctive delivery system. Claims limited to conventional excipients would provide weaker protection.

References

1. U.S. Food and Drug Administration. (n.d.). Megace ES: Megestrol acetate oral suspension prescribing information. DailyMed. https://dailymed.nlm.nih.gov/dailymed/

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

3. U.S. Food and Drug Administration. (2024). Abbreviated new drug application submissions: Refuse-to-receive standards. https://www.fda.gov/

4. U.S. Food and Drug Administration. (n.d.). Hatch-Waxman amendments and abbreviated new drug applications. https://www.fda.gov/ogr#####